Navigation Links
Neuroscience Researcher Has Positive Message for International Alzheimer's Awareness Week, July 6 - 12: 'Even Though World Economy is Declining, Alzheimer's Research is Advancing'

MADISON, Wis., July 7 /PRNewswire/ -- In the midst of generally gloomy worldwide economic news and rising global tensions, an American neuroscience researcher has a message of hope: The answer for Alzheimer's disease and other degenerative diseases of the brain that cause memory loss may be much closer than we realize.

Mark Underwood, president of the Madison, Wisconsin-based biotech company, Quincy Bioscience (, says several recent studies have confirmed a suspected link between unregulated, excessive calcium levels within the neurons and the occurrence of Alzheimer's disease.

"Simply put, we now know that it is 'calcium overload' within the neurons that causes those neurons to stop functioning and brings about cognitive impairment and symptoms associated with Alzheimer's," says Underwood.

"Knowing this link allows us to postulate that an effective treatment for Alzheimer's could be as simple as devising a process to remove the excess calcium ions from calcium-overloaded neurons and thereby restore normal neuronal function."

Underwood says Quincy's own study confirmed that cognitive function could be improved by lowering neuronal calcium concentrations.

"We asked 83 healthy volunteers with self-described poor memory to consume a supplement (Prevagen(R), containing a protein found in jellyfish that buffers calcium by binding to it," says Underwood.

"After 90 days, 63% of the volunteers reported less forgetfulness, 81% reported they required fewer reminders to complete daily tasks, and 74% reported improved ability to find the correct words in a conversation."

Underwood says a key difference between normal, healthy individuals and those with Alzheimer's disease is the rate at which healthy neurons become overloaded with calcium.

"Humans are born able to manufacture their own calcium-binding proteins but we gradually stop producing them at about age 40, and that's when our neurons start to weaken and we begin to experience mild memory loss," says Underwood. "Those with Alzheimer's apparently stop producing these proteins at a faster rate so their cognitive impairment occurs with greater velocity."

Underwood says he is confident that a drug for Alzheimer's can be developed incorporating the jellyfish calcium-binding protein.

"We have shown that normal adults can improve their memory, focus, and concentration by lowering their neuronal calcium," says Underwood. "We are very optimistic that the same compound can now be tested on Alzheimer's patients to assess their level of cognitive improvement."


Quincy Bioscience is a biotech company located in Madison, Wisconsin focused on the discovery, development and commercialization of novel medicines to treat age related memory loss and the diseases of aging. The company's therapeutic products focus on alleviating the consequences of impaired calcium homeostasis - the imbalance of calcium ions thought to be related to neurodegenerative diseases such as Alzheimer's and Parkinson's.


SOURCE Quincy Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
2. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
3. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
4. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
5. Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)
6. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
7. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
10. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
11. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Volumes: Global Analysis (United States, China, Japan, Brazil, United ... to their offering. ... healthcare business planners, provides surgical procedure volume data in ... with an in-depth analysis of growth drivers and inhibitors, ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):